These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 30580125)

  • 1. Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study.
    Gérard JP; Barbet N; Gal J; Dejean C; Evesque L; Doyen J; Coquard R; Gugenheim J; Benizri E; Schiappa R; Baudin G; Benezery K; François E
    Eur J Cancer; 2019 Feb; 108():1-16. PubMed ID: 30580125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Folfirinox' chemotherapy combined with contact x-ray brachytherapy 50kVp and 'CAP50' chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study.
    Mitrea D; Barbet N; Pacé-Loscos T; Scouarnec C; Ben-Dhia S; Baron D; Mineur L; Évesque L; Durand-Labrunie J; Gérard JP; Baudin G; Doyen J
    Cancer Radiother; 2024 Aug; 28(4):323-332. PubMed ID: 39003168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 4. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
    Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.
    Frin AC; Evesque L; Gal J; Benezery K; François E; Gugenheim J; Benizri E; Château Y; Marcié S; Doyen J; Gérard JP
    Eur J Cancer; 2017 Feb; 72():124-136. PubMed ID: 28027515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
    Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
    Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contact radiotherapy boost in association with 'watch and wait' for rectal cancer: initial experience and outcomes from a shared programme between a district general hospital network and a regional oncology centre.
    Smith FM; Al-Amin A; Wright A; Berry J; Nicoll JJ; Sun Myint A
    Colorectal Dis; 2016 Sep; 18(9):861-70. PubMed ID: 26876570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 11. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].
    Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation?
    Sun Myint A; Smith FM; Gollins SW; Wong H; Rao C; Whitmarsh K; Sripadam R; Rooney P; Hershman MJ; Fekete Z; Perkins K; Pritchard DM
    Br J Radiol; 2017 Dec; 90(1080):20170175. PubMed ID: 28937269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
    Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence.
    Benezery K; Montagne L; Evesque L; Schiappa R; Hannoun-Levi JM; Francois E; Thamphya B; Gerard JP
    Clin Transl Radiat Oncol; 2020 Sep; 24():92-98. PubMed ID: 32695890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
    Appelt AL; Pløen J; Harling H; Jensen FS; Jensen LH; Jørgensen JC; Lindebjerg J; Rafaelsen SR; Jakobsen A
    Lancet Oncol; 2015 Aug; 16(8):919-27. PubMed ID: 26156652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 18. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.
    Creavin B; Ryan E; Martin ST; Hanly A; O'Connell PR; Sheahan K; Winter DC
    Br J Cancer; 2017 Jan; 116(2):169-174. PubMed ID: 27997526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced rectal cancer: Preliminary results of rectal preservation after neoadjuvant chemoradiotherapy.
    Vaccaro CA; Yazyi FJ; Ojra Quintana G; Santino JP; Sardi ME; Beder D; Tognelli J; Bonadeo F; Lastiri JM; Rossi GL
    Cir Esp; 2016 May; 94(5):274-9. PubMed ID: 26980259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
    Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
    Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.